Devallois A, Legrand E, Rastogi N
Institut Pasteur, Pointe à Pitre, Guadelooupe, French West Indies.
J Clin Microbiol. 1996 May;34(5):1065-8. doi: 10.1128/jcm.34.5.1065-1068.1996.
A total of 784 specimens collected from 370 individuals between January and August 1995 were analyzed by using the Amplicor Mycobacterium tuberculosis test (Roche Diagnostic System, Basel, Switzerland), a PCR-based test for the direct detection of organisms of the M. tuberculosis complex. The PCR results were compared with standard bacteriological data, including those obtained by acid-fast microscopy, culture, and biochemical identification as well as final clinical diagnosis for each patient. Several parallel controls were used: the kit DNA positive control, 10(3) CFU of M. tuberculosis, and three negative controls for each independent assay. No false-positive PCR results were obtained, and overall, M. tuberculosis was detected in 20 of 370 individuals screened. Five additional patients during the same time were found to be infected with mycobacteria other than tubercle bacilli; their specimens gave positive smear and/or culture test results, but Amplicor tests were always negative. The sensitivity, specificity, positive predictive value, and negative predictive value for the Amplicor MTB test compared with culture per specimen were 76.7, 97.7, 66.0, and 98.6%, respectively. For resolved cases, these values were, respectively, 69.4, 100, 100, and 96.8%; however, the sensitivity and negative predictive value increased to 90.9 and 99.2%, respectively, if PCR-negative nonrespiratory specimens (gastric washings) were not considered. When only specimens from proven tuberculosis patients were considered (n = 114) and the sum of PCR-positive and/or culture-positive samples from proven tuberculosis patients was considered the total number of positive samples, PCR had a sensitivity of 83.3% compared with 71.6% for culture. Results per patient (about three samples each) yielded 100% sensitivity and 100% specificity. We conclude that the Amplicor MTB test is highly specific and rapid for routine use in a clinical laboratory. However, in order to obtain a higher degree of sensitivity, it should be run as an adjunct to smears and culture with at least three samples for each patient, and a single-sample PCR-negative results must be considered carefully because of potential false-negatives.
1995年1月至8月期间,从370名个体中采集了784份标本,采用Amplicor结核分枝杆菌检测试剂盒(罗氏诊断系统,瑞士巴塞尔)进行分析,这是一种基于聚合酶链反应(PCR)的直接检测结核分枝杆菌复合群微生物的检测方法。将PCR结果与标准细菌学数据进行比较,包括抗酸显微镜检查、培养、生化鉴定以及每位患者的最终临床诊断结果。使用了几个平行对照:试剂盒DNA阳性对照、10³CFU的结核分枝杆菌以及每个独立检测的三个阴性对照。未获得假阳性PCR结果,总体而言,在筛查的370名个体中,有20人检测出结核分枝杆菌。在此期间,还发现另外5名患者感染了非结核杆菌的分枝杆菌;他们的标本涂片和/或培养检测结果呈阳性,但Amplicor检测始终为阴性。与每个标本的培养结果相比,Amplicor MTB检测的敏感性、特异性、阳性预测值和阴性预测值分别为76.7%、97.7%、66.0%和98.6%。对于确诊病例,这些值分别为69.4%、100%、100%和96.8%;然而,如果不考虑PCR阴性的非呼吸道标本(洗胃标本),敏感性和阴性预测值分别提高到90.9%和99.2%。仅考虑确诊结核病患者的标本(n = 114),并将确诊结核病患者中PCR阳性和/或培养阳性样本的总和视为阳性样本总数时,与培养结果相比,PCR的敏感性为83.3%,而培养的敏感性为71.6%。每位患者的检测结果(每位患者约三个样本)敏感性和特异性均为100%。我们得出结论,Amplicor MTB检测在临床实验室常规使用中具有高度特异性且快速。然而,为了获得更高的敏感性,应将其作为涂片和培养的辅助检测方法,每位患者至少检测三个样本,并且由于可能存在假阴性,对于单个样本PCR阴性的结果必须谨慎考虑。